Updates are available Correction dated 2022-08-25
Click to view Correction: https://doi.org/10.1038/s41467-022-32817-9
-
Authors
Deng, Yexuan
Diepstraten, Sarah T.
Potts, Margaret A. https://orcid.org/0000-0001-9796-9683
Giner, Göknur
Trezise, Stephanie https://orcid.org/0000-0002-7511-3291
Ng, Ashley P. https://orcid.org/0000-0001-9690-0879
Healey, Gerry
Kane, Serena R.
Cooray, Amali https://orcid.org/0000-0003-2981-9282
Behrens, Kira https://orcid.org/0000-0003-0800-8472
Heidersbach, Amy
Kueh, Andrew J.
Pal, Martin https://orcid.org/0000-0002-1563-5426
Wilcox, Stephen
Tai, Lin
Alexander, Warren S.
Visvader, Jane E. https://orcid.org/0000-0001-9173-6977
Nutt, Stephen L. https://orcid.org/0000-0002-0020-6637
Strasser, Andreas https://orcid.org/0000-0002-5020-4891
Haley, Benjamin
Zhao, Quan https://orcid.org/0000-0002-8533-1938
Kelly, Gemma L. https://orcid.org/0000-0002-6533-1201
Herold, Marco J. https://orcid.org/0000-0001-7539-7581
- License Information
-
More Information
Article History
Received: 29 August 2021
Accepted: 29 July 2022
First Online: 12 August 2022
Change Date: 25 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-32817-9
Competing interests
: The Walter and Eliza Hall Institute receives milestone and royalty payments related to venetoclax. A.S. is consulting for Genentech and Servier. A.H. and B.H. are employees of Genentech, Inc. and shareholders of Roche. The remaining authors declare no competing interests.
